GlassScriptPhysician profile
Daniel Takeo Kasuga
NPI 1568786176
$9,272.37
in general payments reported to CMS, 2019-2025
21 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 77% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $99.93 · 2021: $407 · 2022: $1,068 · 2023: $1,570 · 2024: $4,079 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,565 · Consulting Fee: $2,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,564.50 |
| Consulting Fee | $2,290.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $3,351.77 | 2019-2025 | Vabysmo, Susvimo |
| Regeneron Pharmaceuticals, INC. | $1,081.60 | 2021-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $984.23 | 2019-2025 | Constellation, Unity |
| Regeneron Healthcare Solutions, INC. | $731.36 | 2019-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $538.69 | 2023-2025 | Izervay |
| Carl Zeiss Meditec USA, INC. | $308.47 | 2023-2024 | Veracity Surgical, Retina Workplace |
| Alimera Sciences, INC. | $299.47 | 2022-2024 | Yutiq, Iluvien |
| Allergan, INC. | $273.38 | 2019-2021 | |
| Coherus Oncology, INC. | $228.98 | 2023 | |
| Eyepoint US, INC. | $204.61 | 2019-2022 | |
| Amgen INC. | $195.74 | 2025 | Pavblu |
| Biogen, INC. | $164.60 | 2023 | |
| Apellis Pharmaceuticals, INC. | $147.67 | 2023-2025 | Syfovre |
| Sandoz INC. | $142.71 | 2024-2025 | Cimerli |
| Bausch & Lomb Americas INC. | $111.05 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $111.04 | 2025 | Iheezo |
| Iridex Corporation | $105.89 | 2022 | |
| Novartis Pharmaceuticals Corporation | $100.40 | 2019 | |
| Spark Therapeutics, INC. | $99.00 | 2019 | |
| US Oncology Corporate, INC. | $69.62 | 2024 | |
| Genentech, INC. | $22.09 | 2024 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kasuga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.